STERIS (STE) Stock Forecast & Price Target

Steris is benefiting from a solid FQ1-27 showing in which revenue was essentially in line and EPS beat by a dime, reinforcing confidence that prior bear concerns about the FY'27 guidance were overstated. Healthcare organic growth of 6% was driven by 10% service growth and 9% consumables growth, while orders rose 8% and backlog reached 3-year highs, supporting better visibility into equipment revenue and margin expansion with segment EBIT margin up 60 bps to 24.8%. Management also guided to 6-7% organic revenue growth, 7-8% AST growth, gross leverage of about 1.2x, and a $1B buyback program, all of which point to durable cash generation, disciplined capital allocation, and sustained mid- to high-single-digit growth.

Steris is facing a muted AST trajectory, with 5% organic growth and 6% services growth reflecting lighter volume against a tough 13% first-half comp and ongoing customer destocking, while management’s unchanged +7-8% full-year guide still implies only gradual improvement. Segment operating margin fell 60 bps because of higher depreciation tied to new facilities, signaling a persistent drag on profitability that limits near-term earnings leverage. More broadly, the stock is exposed to macro and policy risks, including weaker global healthcare spending, unfavorable tariff changes, and new FDA regulatory actions, all of which could pressure demand and margin expansion.